Missense mutations in SARS-CoV2 genomes from Indian patients
Missense mutations in SARS-CoV2 genomes from Indian patients
复制标题
DOI：
10.1016/j.ygeno.2020.08.021
复制
发表时间：
2020-11-01
期刊：
影响因子：
4.4
通讯作者：
Jana, Siddhartha Sankar
中科院分区：
文献类型：
--
作者：
Hassan, Sk. Sarif;Choudhury, Pabitra Pal;Jana, Siddhartha Sankar
严重急性呼吸综合征冠状病毒-2 （SARS-CoV2）在若干国家的遗传多样性概括了世界范围内的遗传多样性。在本研究中，考虑到截至2020年5月128名印度患者的SARS-CoV2基因组中错义突变的变化，从而提出了一些关键发现和一些假设。这些基因组中不同基因的突变显示了SARS-CoV2病毒在序列上的广泛遗传变异和快速进化。在所研究的SARS-CoV2基因组中存在独特突变可能导致其衰减。截至2020年7月14日，在印度的339个基因组中，很少有基因（如ORF6、ORF10）没有任何突变。此外，E蛋白只包含一个突变。这可能表明，设计一种针对ORF6、ORF10和E基因的治疗方法可能对控制COVID-19大流行（特别是在印度）有有益的影响。
The genetic diversity of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) in several countries sums up to worldwide genetic diversity. In this present study, variations in terms of missense mutations among the SARS-CoV2 genomes from 128 Indian patients, as of May 2020, are accounted and thereby some key findings with some hypotheses were made. These mutations across various genes of these genomes show wide genetic variations in sequence and rapid evolution of SARS-CoV2 virus. The presence of unique mutations in the studied SARS-CoV2 genomes may led to their attenuation. Few Genes such as ORF6, ORF10 are free from any mutations in the Indian context of 339 genomes observed as of 14th July 2020. Further, E protein contains only one mutation. This may suggest that designing a therapeutic approach against ORF6, ORF10 and E genes may have a beneficial effect in controlling COVID-19 pandemic especially in India.